Diagnostic techniques and prognostic indicators

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Heaney JLJ et al. Br J Haematol. 2017 Jun 1. doi: 10.1111/bjh.14753. [Epub ahead of print]. Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease. Hofmann JN et al. Obesity (Silver Spring). 2017 Jun 11. doi: 10.1002/oby.21894. [Epub ahead of print]. Diffusion-weighted whole-body MRI for…

Details

Related conditions

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Kaufman GP et al. Blood. 2017 Jun 14. pii: blood-2017-01-763599. doi: 10.1182/blood-2017-01-763599. [Epub ahead of print]. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Jung SH et al. Oncotarget. 2017 Jun 16. doi: 10.18632/oncotarget.18535. [Epub ahead of…

Details

Emerging treatments

MEK inhibitors in oncology: a patent review (2015-Present). Mahapatra DK et al. Expert Opin Ther Pat. 2017 Jun 19:1-20. doi: 10.1080/13543776.2017.1339688. [Epub ahead of print]. Elotuzumab as a novel anti-myeloma immunotherapy. Radhakrishnan SV et al. Hum Vaccin Immunother. 2017 Jun 12:1-7. doi: 10.1080/21645515.2017.1327487. [Epub ahead of print]. Sending CAR T Cells After Multiple Myeloma. [No authors listed]. Cancer Discov. 2017 Jun 6. doi: 10.1158/2159-8290.CD-NB2017-088. [Epub…

Details

Biology and genetics

A novel dual inhibitor of microtubule and Bruton’s Tyrosine Kinase inhibits survival of multiple myeloma and osteoclastogenesis. Pandey MK et al. Exp Hematol. 2017 Jun 21. pii: S0301-472X(17)30233-3. doi: 10.1016/j.exphem.2017.06.003. [Epub ahead of print]. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Laganà A et al. Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.197. [Epub ahead of print]. Changes…

Details

General

Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Hulin C et al. Leuk Res. 2017 May 31;59:75-84. doi: 10.1016/j.leukres.2017.05.019. [Epub ahead of print]. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Gregersen H et al. Cancer Med. 2017 Jun 22. doi: 10.1002/cam4.1128. [Epub ahead of print]. Recent advances in understanding multiple myeloma.…

Details

Supportive treatments

Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease. Whittle RM et al. J Clin Apher. 2017 Jun 13. doi: 10.1002/jca.21541. [Epub ahead of print]. Comparison of Operative Time with Conventional Fluoroscopy versus Spinal Neuronavigation in Instrumented Spinal Tumor Surgery. Miller JA et al. World Neurosurg. 2017 Jun 9. pii: S1878-8750(17)30908-7. doi: 10.1016/j.wneu.2017.06.016.…

Details

Complications of myeloma and its treatments

Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Heusschen R et al. Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323272. [Epub ahead of print]. An unusual presentation of multiple myeloma with unilateral sudden vision loss: A case report. Wu PW et al. Medicine (Baltimore). 2017 Jun;96(25):e7277. doi: 10.1097/MD.0000000000007277. Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation. Ragbourne SC et al. Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):340-346.…

Details

Current treatments

Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil. Vigolo S et al. Hematol Oncol Stem Cell Ther. 2017 Jun 15. pii: S1658-3876(17)30082-1. doi: 10.1016/j.hemonc.2017.05.027. [Epub ahead of print]. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Vogl DT et al. Leuk Lymphoma. 2017 Jun 22:1-8. doi: 10.1080/10428194.2017.1334125. [Epub ahead of…

Details

Publication of consensus statement on the use of plerixafor in myeloma or lymphoma patients

A consensus statement identifying the best use of plerixafor to facilitate autologous peripheral stem cell collection to support high-dose therapy and stem cell transplantation in myeloma or lymphoma patients has been published recently in the Journal of Clinical Apheresis. Written by the Plerixafor Usage Working Party Group involving representative clinicians from the UK and Republic…

Details